FDA Sticks To Its Guns On Biosimilar Naming

 
• By David Wallace
  
Crowd
US Has Doubled Down On Biosimilar Naming Conventions That Set It Apart From The Crowd • Source: Shutterstock
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Intelligence

More from In Vivo